Table 1.
Demographics of the patients with ndMM or rrMM
| ndMM | rrMM |
|||
|---|---|---|---|---|
| Total | LENR | POMR | ||
| Number of patients (number of samples) | 198 (198) | 386 (418) | 269 (273) | 55 (83) |
| Mean study entry age, y (95% CI) | 57.2 (56.3-58.2) | 66.8 (66-67.5) | 66.9 (66-67.8) | 63.5 (61.4-65.6) |
| Mean time since diagnosis, y (95% CI) | - | 5.9 (5.6-6.2) | 5.8 (5.5-6.1) | 6.8 (6.1-7.5) |
| Sex | ||||
| Male/total patients with data (%) | 93/149 (62.4) | 213/386 (55.2) | 147/269 (54.6) | 31/55 (56.4) |
| Female/total patients with data (%) | 56/149 (37.6) | 173/386 (44.8) | 122/269 (45.4) | 24/55 (43.6) |
| ISS | ||||
| I/total patients with data (%) | 55/156 (35.3) | 97/315 (30.8) | 77/226 (34.1) | 9/46 (19.6) |
| II/total patients with data (%) | 66/156 (42.3) | 113/315 (35.9) | 82/226 (36.3) | 24/46 (52.2) |
| III/total patients with data (%) | 35/156 (22.4) | 105/315 (33.3) | 67/226 (29.6) | 13/46 (28.3) |
| Number of patients that received stem cell transplants (%) | 87/187 (46.5) | 232/352 (65.9) | 165/253 (65.2) | 43/55 (78.2) |
| BORT | ||||
| Exposed/total patients with data (%) | - | 320/320 (100) | 239/239 (100) | 54/54 (100) |
| Refractory/total patients with data (%) | - | 231/310 (74.5) | 195/236 (82.6) | 33/47 (70.2) |
| DAR | ||||
| Exposed/total patients with data (%) | - | 38/38 (12.2) | 14/14 (100) | 23/23 (100) |
| Refractory/total patients with data (%) | - | 21/38 (55.3) | 4/14 (28.6) | 17/23 (73.9) |
| Translocation | ||||
| t(4;14) (%) | 24 (12.1) | 45 (11.7) | 37 (13.8) | 5 (9.1) |
| t(8;14) (%) | 12 (6.1) | 25 (6.5) | 18 (6.7) | 3 (5.5) |
| t(11;14) (%) | 41 (20.7) | 80 (20.7) | 52 (19.3) | 14 (25.5) |
| t(14;16) (%) | 5 (2.5) | 6 (1.6) | 5 (1.9) | 1 (1.8) |
| t(14;20) (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| t(6;14) (%) | 5 (2.5) | 6 (1.6) | 2 (0.7) | 2 (3.6) |
| t(8;22) (%) | 11 (5.5) | 12 (3.1) | 9 (3.3) | 2 (3.6) |
Patients are classified by disease setting (ndMM vs rrMM) and among patients with rrMM, cohorts are designated by refractory status to lenalidomide or pomalidomide. Translocation prevalence is derived from genomics data. BORT, bortezomib; DAR, daratumumab; ISS, International Staging System.